



## Prescription Pharmaceutical Products

PRODUCT	INDICATION <sup>1,3</sup>	TERRITORY <sup>2</sup>						PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
<b>Oncology/Hematology</b>								
<b>Minjuvi® (tafasitamab)</b>	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Submitted	Submitted	Submitted	Pre-registration	Incyte
<b>Pemazyre®</b>	Metastatic cholangiocarcinoma		Submitted	Submitted	Submitted	Submitted	Pre-registration	Incyte
<b>Akynzeo®</b>	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22				Helsinn
<b>Aloxi®</b>	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22						Helsinn
<b>Fostamatinib</b>	Treatment of chronic immune thrombocytopenia		Submitted	Pre-registration	Submitted	Submitted		Rigel
<b>Nerlynx®</b>	Extended adjuvant breast cancer and metastatic breast cancer	Q4-19						Puma
<b>Trelstar®</b>	Advanced prostate cancer	Q2-20						Debiopharm
<b>Vidaza®</b>	Myelodysplastic syndrome		Q2-10					Celgene (BMS)
<b>Abraxane®</b>	Metastatic pancreatic cancer		Q4-17					Celgene (BMS)
<b>Halaven®</b>	Metastatic breast cancer and soft tissue sarcoma		Q4-17	Q4-19	Q2-22		Marketed	Eisai
<b>Lenvima®</b>	Differentiated thyroid cancer and unresectable hepatocellular carcinoma		Q4-17		Q1-22		Marketed	Eisai
<b>Lenvima®</b>	Advanced renal cell cancer		Q4-17				Marketed	Eisai
<b>BGx</b>								
<b>Ladevina®</b>	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Marketed	Own
<b>Ladevina®</b>	Mantle Cell Lymphoma; follicular lymphoma			2011			Marketed	Own
<b>Zyvalix®</b>	Metastatic prostate cancer			2014	Q2-18		Marketed	Own
<b>Karfib®</b>	Relapsed or refractory multiple myeloma			Q4-19	Approved		Marketed	Own
<b>Leprid®</b>	Palliative treatment of advanced prostate cancer			2007			Marketed	Own
<b>Rembre®</b>	Chronic myeloid leukemia			2013	Q1-22		Marketed	Own
<b>Palbocil®, Bapocil®</b>	Breast cancer			Q1-23	Submitted		Approved	Own
<b>Xetrane®</b>	Multiple myeloma			Q2-19	Submitted		Approved	Own
<b>Xetrane®</b>	AIDS-related Kaposi sarcoma			Q2-22				Own

<sup>1.</sup> The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

<sup>2.</sup> The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

<sup>3.</sup> The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.



PRODUCT	INDICATION <sup>1,2</sup>	TERRITORY <sup>3</sup>						PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	Others	
<b>Infectious Diseases</b>								
<b>AmBisome®</b>	Invasive fungal infection		1997					Gilead
<b>Cresemba®</b>	Invasive fungal infection		Q2-20	Q3-19	Q3-19	Q2-19	Marketed	Basilea
<b>Impavido®</b>	Leishmaniasis						Marketed	Own
<b>BGx</b>								
<b>Dolufevir®</b>	HIV infection			Q2-21				Own
<b>Other Specialty</b>								
<b>Exelon®</b>	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Marketed	Own
<b>Ibsrela®</b>	IBS-C	Q1-21						Ardelyx
<b>Salofalk®</b>	Ulcerative colitis			2007	Pre-2019		Marketed	Dr. Falk
<b>Ursofalk®</b>	Primary biliary cirrhosis			2007	Pre-2019		Marketed	Dr. Falk
<b>Imvexxy®</b>	Moderate-to-severe dyspareunia	Q1-24						TXMD
<b>Bijuva®</b>	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24						TXMD
<b>BGx</b>								
<b>Fibridoner®</b>	Idiopathic pulmonary fibrosis			2017			Marketed	Own
<b>Toliscriin® DPI</b>	Pseudomonas aeruginosa lung infection in patients with cystic fibrosis			2017			Marketed	Own
<b>Toliscriin® 1-2</b>	Severe acute or resistant chronic infections due to colistin sensitive strains of gram-negative pathogenic bacilli			2017			Marketed	Own
<b>Tobradosa Haler®</b>	Chronic lung infections due to Pseudomonas aeruginosa			2018			Marketed	Own

<sup>1.</sup> The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

<sup>2.</sup> The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

<sup>3.</sup> The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.



## Pipeline and Products in Early Launch Stage

The Company expects that its pipeline and products in early launch stage could achieve total revenues of over \$150,000,000 combined in their peak years. The products in early launch stage are within two years from the commercial launch date on a country by country basis.

PRODUCT	INDICATION OR THERAPEUTIC AREA <sup>1,3</sup>	TERRITORY <sup>2</sup>					LAUNCH / EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
<b>Oncology/Hematology</b>							
<b>Minjuvi® (tafasitamab)</b>	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)		Q1-24	Submitted	Submitted	Submitted	2024 -2025
<b>Pemigatinib</b>	Metastatic cholangiocarcinoma		Submitted	Submitted	Submitted	Submitted	2025-2026
<b>Fostamatinib</b>	Treatment of chronic immune thrombocytopenia		Submitted	Pre-registration	Submitted	Submitted	2025-2026
<b>Palbocil®, Bapocil®</b>	Breast Cancer				Submitted		2025
<b>Xetrane®</b>	Multiple myeloma				Submitted		2025
<b>Karfib®</b>	Relapsed or refractory multiple myeloma				Approved		2025
<b>Rembre®</b>	Chronic myeloid leukemia						2024
<b>O501</b>	Oncology/Hematology			Development			2025
<b>O502</b>	Oncology/Hematology			Submitted			2025
<b>H401</b>	Oncology/Hematology		Development		Development	Development	2027 - 2028
<b>H402</b>	Oncology/Hematology		Development				2028 - 2029
<b>Other Specialty</b>							
<b>Imvexxy®</b>	Moderate-to-severe dyspareunia	Q1-24					2024
<b>Bijuva®</b>	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24					2024
<b>JORNAY PM®</b>	Attention-Deficit Hyperactivity Disorder (ADHD)	Submitted	Pre-registration			Pre-registration	2026-2027
<b>Qelbree™</b>	Attention-Deficit Hyperactivity Disorder (ADHD)		Pre-registration				2026-2027
<b>IPX203</b>	Parkinson's disease	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	2027-2028
<b>C401 (Neurology)</b>	Other Specialty		Development	Development	Submitted		2025 - 2026
<b>C402/403 (Neurology)</b>	Other Specialty		Development		Development	Development	2026 - 2027

<sup>1.</sup> The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.

<sup>2.</sup> The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.

<sup>3.</sup> The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.